Lupin Sets Record with Maximum Diabetes Patients Onboarded in Real-World Evidence Study

Mumbai (Maharashtra) [India], April 22: In a groundbreaking achievement, Lupin Limited has set a new benchmark in Real-World Evidence (RWE) research by successfully onboarding 67,802 diabetes patients across 1,336 clinics for one of India’s largest single RWE studies conducted for vildagliptin and its combinations.

The study, which was officially confirmed on March 15, 2025, aimed to capture vital real-world data including demographics, disease duration, laboratory investigations, and treatment outcomes. The insights gathered are expected to significantly contribute to the simplification of diabetes management across the country.

The initiative was spearheaded under the campaign “Adding Colours to Diabetes Blues” by Verifica, Lupin’s innovative diabetes therapy. The campaign not only focused on advanced clinical treatment but also included a wide range of patient benefit initiatives such as free screenings and authentic diabetes management resources tailored to the Indian context.

Congratulating the team on the milestone, Mr. Gagan Arora, Cluster Head, Lupin Limited, said,
“This achievement reflects Lupin’s unwavering commitment to advancing diabetes care in India. I wholeheartedly congratulate and thank our entire Lupin team and the healthcare professionals across the country who came together to make this possible. Your collective efforts have created a moment of pride and a step forward in patient-centric care.”

Commenting on the significance of the study, Dr. Sanjay Kalra, one of the principal investigators, noted, “Real-World Evidence studies are essential for understanding how therapies perform in the diverse and dynamic Indian population. This study’s scale and depth provide much-needed insights that can bridge the gap between clinical trials and actual patient experiences.”

This landmark study reinforces Lupin’s leadership in RWE-based research and its dedication to transforming diabetes management for Indian patients through evidence-backed, patient-first solutions.